开能健康：公司自主研发的“YT001注射液”已获批准开展I/IIa期临床试验

Core Viewpoint - The company holds a positive outlook on the prospects of the stem cell therapy industry and has been actively involved in this field since 2014, establishing the Yuaneng Cell Technology Group [2] Group 1: Company Strategy and Developments - The company has made significant investments in the cell therapy sector, aligning with national policy support for stem cell treatments [2] - Through acquisitions of equity in subsidiaries of Yuaneng Group, the company has secured key assets including land in Zhangjiang, patent licenses in the cell industry, and clinical trial approvals for "YT001 injection" [2] - The company's layout in the stem cell therapy field includes several business segments: 1. Cell preparation services for large-scale production of cell therapy drugs and customized clinical research cells for pharmaceutical companies and research institutions [2] 2. Development of proprietary cell preparation reagents, establishing itself as a key supplier in the industry chain [2] 3. Research and development of cell technology products, with "YT001 injection" approved for I/IIa clinical trials, aiming for commercialization through product launch, technology transfer, or revenue sharing [2] 4. Application of stem cell therapy and related solutions in pet health and anti-aging [2] Group 2: Industry Participation and Intellectual Property - The company actively participates in the formulation of industry standards and holds multiple authorized patents and software copyrights, providing a solid technical foundation and intellectual property protection for the development of stem cell therapy [2]